Compare CVS Health Corp (CVS) vs Honest Company Inc (HNST) Price & Performance

CVS Health trades at $94.70, down 1.01% with strong technical support at $93-$91 levels. The company reported robust Q2 2026 earnings of $2.58 per share, beating estimates by 38%, while raising full-year guidance. Revenue growth accelerated to 7.3% year-over-year, driven by Aetna's recovery and retail strength. Analyst consensus remains overwhelmingly bullish with 84% buy ratings and a $115.90 price target representing 22% upside potential.

CVS presents compelling value with a 0.29 P/S ratio and positive earnings momentum, though net margins remain thin at 1.18%. Key risks include 2027 PBM pressure and healthcare regulatory changes. The stock's current technical weakness near support levels offers potential entry point for long-term investors seeking exposure to integrated healthcare services.

HNST trades at $5.21, down 0.38% on the day, with a bullish technical signal from moving averages despite overbought RSI readings. The company reported mixed Q2 2026 results with an earnings beat but declining revenue, while maintaining negative profitability metrics including a -3.56% net income margin. Recent strategic exits have impacted top-line performance but improved underlying profitability trends.

The stock faces headwinds from inconsistent earnings performance and negative margins, though improved cash flow and strategic repositioning offer potential upside. Analyst sentiment remains cautious with 30% buy ratings, reflecting concerns about sustained profitability amid ongoing business transformation efforts.